

LIDDS participates in BIO-Europe Spring and EACR Immuno-Oncology Meetings

UPPSALA, SWEDEN – LIDDS AB (publ) announces today that the company will participate in two important events this spring. Firstly, the BIO-Europe Spring meeting, taking place in Basel between 20 and 22 March 2023. Secondly, the EACR Defence is the Best Attack: Immuno-Oncology Breakthroughs conference, taking place in Barcelona between 9 and 11 May 2023.

LIDDS' CEO Anders Månsson will participate in the BIO-Europe Spring meeting, which is physically organized in Basel, Switzerland. BIO-Europe is the premier European partnering event and provides LIDDS with opportunities for both collaboration and partner discussions as well as investor meetings. LIDDS' attendance will be in conjunction with our partnership with Alira Health to drive forward our on-going business development activities.

LIDDS' Head of Preclinical, Erwin Brenndörfer will attend the European Association for Cancer Research (EACR) meeting titled "Defence is the Best Attack: Immuno-Oncology Breakthroughs" after submitting an abstract on LIDDS' Nanoimod project, and successfully being accepted to deliver a poster presentation. Erwin will share more details on the strong progress with this project as LIDDS prepares for a possible Phase I initiation this year.

For additional information, please contact

Anders Månsson, CEO
Phone: +46 (0)70 860 47 38
E-mail: anders.mansson@liddspharma.com

Jenni Björnulfson, CFO
Phone: +46 (0)70 855 38 05
E-mail: jenni.bjornulfson@liddspharma.com

LIDDS' Certified Adviser is Redeye AB

LIDDS in brief:

LIDDS is a Swedish drug delivery company based on the proprietary technology NanoZolid®. With NanoZolid®, LIDDS can formulate drugs for local/intratatumoral administration, with a maintained and controlled release for up to six months. The technology is versatile, can be used across different drug classes and can solve problems within many indication areas, mainly within oncology. LIDDS offers the NanoZolid® technology to partners and has developed its own pipeline focused on oncology, where the technology enables delivery of a local and high drug dose, administered over time with very limited side effects. LIDDS has a broad pipeline with several projects in clinical development, both in early and late-stage clinical phase, and projects about to enter clinical development. The company is listed on Nasdaq First North Growth Market.

Attachments

LIDDS participates in BIO-Europe Spring and EACR Immuno-Oncology Meetings